검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Afatinib Dimaleate |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin signaling pathway |
MoA Biomarker | biomarker and its implication in lung adenocarcinoma |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial.. To evaluate the bioequivalence of two different afatinib dimaleate formulations in healthy Chinese subjects under fasting conditions and to assess their pharmacokinetic and safety profiles. This randomized, open-label, 2-perio… |
Clinical Primary efficacy | ORR 96% |
Clinical ORR | 96% |
Clinical OS | 24.44 |
Clinical Result source | ClinicalTrials.gov NCT04179890 |
Clinical Data Tier / Score | A · 73 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Afatinib Dimaleate |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin signaling pathway |
MoA Biomarker | biomarker and its implication in lung adenocarcinoma |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial.. To evaluate the bioequivalence of two different afatinib dimaleate formulations in healthy Chinese subjects under fasting conditions and to assess their pharmacokinetic and safety profiles. This randomized, open-label, 2-perio… |
Clinical Primary efficacy | ORR 96% |
Clinical ORR | 96% |
Clinical OS | 24.44 |
Clinical Result source | ClinicalTrials.gov NCT04179890 |
Clinical Data Tier / Score | A · 73 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교